Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ondexxya | andexanet alfa | Reversal of FXa inhibitor anticoagulant effects | Do not reimburse | Complete | ||
Onglyza | Saxagliptin | Diabetes mellitus, type 2 | Withdrawn | |||
Onglyza | Saxagliptin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
Onglyza | Saxagliptin | Diabetes mellitus (Type 2) | Do not list | Complete | ||
Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
Onivyde | Irinotecan Liposome | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Onpattro | patisiran | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Withdrawn | |||
Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
Onstryv | safinamide | Parkinson's disease | Do not reimburse | Complete |